Improved understanding of the immunobiology of cancer tissues and the tumor microenvironment (TIME) has led to the emergence of highly effective anti-cancer therapies related to immune checkpoint blockers (ICB) such as PD1, PDL1, and CTLA-4 [23]. The gene discussed is CTLA4; the disease is neoplasm.